The staging value of sentinel lymph node biopsy for breast cancer: translating pathologic findings to clinical practice
Review Article

The staging value of sentinel lymph node biopsy for breast cancer: translating pathologic findings to clinical practice

Jean Bao, Cory Donovan, Alice Chung, Armando E. Giuliano

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Contributions: (I) Conception and design: J Bao, A Chung, AE Giuliano; (II) Administrative support: A Chung, AE Giuliano; (III) Provision of study materials or patients: A Chung, AE Giuliano; (IV) Collection and assembly of data: J Bao; (V) Data analysis and interpretation: J Bao, C Donovan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Armando E. Giuliano, MD. 310 N. San Vicente Blvd, 3rd floor, Los Angeles, CA 90048, USA. Email: Armando.Giuliano@cshs.org.

Abstract: Axillary nodal status is an important prognostic factor in guiding locoregional and systemic treatment for breast cancer. Sentinel lymph node biopsy (SNB) has revolutionized axillary staging by replacing axillary lymph node dissection (ALND) in node-negative women. Even in select patients whose sentinel lymph nodes (SLNs) contain metastases, SNB alone has become an accepted method of managing the axilla. Identification of micrometastases through immunohistochemical analysis of SLNs that are tumor-free on hematoxylin and eosin staining (H&E) does not confer additional clinical benefit. The use of SNB after neoadjuvant chemotherapy (NAC) remains controversial. In addition to axillary nodal status, tumor biology plays an increasingly important role in guiding therapeutic decisions.

Keywords: Sentinel node; axillary staging; histopathologic analysis


Submitted Jan 19, 2016. Accepted for publication Feb 10, 2016.

doi: 10.21037/cco.2016.03.17


Introduction

Axillary nodal status is an important prognostic factor in breast cancer and is used to guide locoregional and systemic treatment decisions. Sentinel lymph node biopsy (SNB) has revolutionized axillary staging by replacing axillary lymph node dissection (ALND) in node-negative women. There is indisputable evidence that SNB is an effective and accurate method of staging the axilla in clinically node-negative breast cancer with less morbidity than ALND. SNB alone is now the standard method of managing the axilla with sentinel lymph nodes (SLNs) that are histologically free of tumor (1). In select patients with limited metastases in the SLN, SNB alone has become an acceptable approach whereas ALND has traditionally been the standard of care. Thorough pathologic interrogation of the SLN has led to increased detection of occult metastases whose clinical significance was previously greatly debated. Biologic factors play an increasingly important role in guiding therapeutic decisions, in addition to the lymph node tumor status. In this article, these issues will be addressed in detail.


Feasibility of SNB

The feasibility of intraoperative SNB in breast cancer with lymphatic mapping using isosulfan blue dye was first reported by Giuliano et al. in 1994 (2). Their prospective study demonstrated SNB to be a minimally invasive and highly accurate method of staging the axilla when SLNs were evaluated intraoperatively with frozen section analysis and postoperatively with hematoxylin and eosin staining (H&E) plus cytokeratin immunohistochemistry (IHC) (3). The sentinel node concept was subsequently validated by several groups. Our group reported proof of principle by performing complete histopathologic evaluation of SLNs and non-SLNs using H&E and IHC for all H&E-negative axillary lymph nodes and found the probability of non-SLN involvement to be less than 0.1% when the SLN is tumor-free by H&E and IHC. We also demonstrated the false-negative rate (FNR) of SNB to be 0.97% (4). A multicenter SLN validation study employing similar rigorous histopathologic examination of axillary lymph nodes concluded that SLNs are predicative of the final axillary nodal status with SLNs more likely than non-SLNs to harbor occult metastases (5).

Multiple multicenter randomized SNB trials confirmed the feasibility and accuracy of SNB as an axillary staging procedure thus enabling widespread clinical application of this technique (6-9). The SLN identification rate ranged from 95% to 98.7% with accuracy of 95% to 97% and a FNR from 5.5% to 16.7%. The NSABP B-32 trial randomized 5,611 patients with clinically node-negative invasive breast cancer to either SNB plus ALND or to SNB alone with ALND only if SLNs contained metastasis. The SLNs were evaluated at 2 mm sections with H&E, and IHC was performed only in cases of suspicious or negative findings on H&E. With the use of both blue dye and radioactive tracer for lymphatic mapping, the SLN identification rate was 97.2%, accuracy 97.1%, and FNR 9.8% (6).


Histopathologic processing of SLNs

Guidelines were established on focused histopathologic analysis of SLNs for more accurate axillary staging through more intensive histopathologic review to detect more SLN metastases (10). The SLN should be bivalved along the longitudinal axis, serially sectioned at 1.5 to 2 mm intervals, and each interval block is serially sectioned at three levels. Metastases in the SLN detected by H&E or IHC are classified by size: macrometastases (>2 mm), micrometastases (≤2 and >0.2 mm), or isolated tumor cells (ITCs) (≤0.2 mm). ITCs were further defined by the 7th edition of the American Joint Committee on Cancer (AJCC) as clusters of cells ≤0.2 mm or nonconfluent or nearly confluent clusters of cells not exceeding 200 cells in a single histologic cross section of a lymph node (11).


Impact of SNB with negative SLNs

Multiple randomized trials have demonstrated that when the SLN is tumor-free, observation alone confers similar regional control and survival compared to SNB followed by ALND (12-15). In NSABP-B32, 3,089 patients had pathologically negative SLNs, 99.9% of whom had follow-up data. At 95.6 months, there was no statistically significant difference between the SNB plus ALND group and the SNB-only group with respect to regional recurrence (RR) (0.4% vs. 0.7%), 8-year overall survival (OS) (91.8% vs. 90.3%) and 8-year disease-free survival (DFS) (82.4% vs. 81.5%) (12). Veronesi et al. demonstrated in their single-institution randomized trial similar results comparing SNB plus ALND to SNB-only when the SLN is free of metastasis. At 102 months, there was no statistically significant difference in OS (89.7% vs. 93.5%) or in DFS (89.9% vs. 88.8%) with only 2 axillary recurrences both in the SNB-only group (13). Intraoperative frozen sections followed by permanent section analyses were performed on SLNs in both studies. Like NSABP-B32, Veronesi et al. examined the SLN in multiple sections with H&E and used IHC only in case of negative or suspicious SLNs. These results demonstrate that SNB provides regional nodal control equivalent to ALND when the SLN is free of tumor. In the Sentinella trial, despite the high FNR of 16.7%, only one axillary recurrence in the SNB-only group occurred at 55.6 months, and there was no difference in OS and DFS (15). Hence, some occult lymph node metastases may not progress to become clinically significant, especially in the modern day era of systemic therapy. SNB has been proven to be safe, reliable and effective and has become the standard procedure for staging clinically node-negative invasive breast cancer.


Management of the axilla with positive SLNs

The standard management of a patient with metastasis in the SLN has traditionally been ALND. However, several retrospective studies have documented similar regional recurrence and survival rates in select patients with a tumor-positive SLN who did not undergo completion ALND compared to those who did. Bilimoria et al. identified 97,314 clinically node-negative patients found to have SLN metastases from the National Cancer Database from 1998–2005, of whom 20.8% underwent SNB alone. Amongst patients with SLNs containing micrometastases, there was no difference in RR and survival between the SNB-only group and the SNB plus completion ALND group at 63 months. With respect to nodal macrometastases, the outcomes were better with ALND, but the difference was not statistically significant (16). Similar results were reported from a review of the Surveillance, Epidemiology, and End Results (SEER) database with 26,986 SLN-positive patients, among whom 16.4% had SNB alone. From 1998 to 2004, the proportion of patients with SLN micrometastases increased from 21% to 37.8%. At a median follow up of 50 months, no survival advantage was seen with completion ALND among those with micrometastases in the SLNs (17).

Nomograms based on histopathologic data have been developed to predict the risk of additional nodal disease beyond the SLN and to help the clinician determine who may be at increased risk for harboring non-SLN metastases and therefore might benefit from a completion ALND (18-20). The clinical usefulness of nomograms has been met with variable degree of success. Memorial Sloan-Kettering Cancer Center conducted a retrospective review of 1,960 SLN-positive patients from 1997 to 2004. The 287 patients who did not have completion ALND were older, had more favorable tumors, a higher rate of breast conservation, and had a lower risk of residual axillary disease as predicted by their nomogram. At 23–30 months follow-up, the axillary recurrence was marginally higher in the SNB-only group than in the SNB plus ALND group (2% vs. 0.4%, P=0.004) (21).

The omission of completion ALND in SLN-positive patents was examined in American College of Surgeons Oncology Group (ACOSOG) Z0011 and After Mapping of the Axilla: Radiotherapy Or Surgery (AMAROS) trials, both prospective randomized clinical trials. The ACOSOG Z0011 was a prospective multicenter Phase III non-inferiority trial that randomized 891 patients with clinical T1-2N0M0 disease but pathologically tumor-positive SLNs to completion ALND or to SNB alone (22). The SLN was documented to contain metastasis by frozen section, touch preparation, or H&E on permanent section. Positive SLNs by IHC alone were excluded. All patients received breast conservation surgery (BCS) and whole breast irradiation (WBI), and 97% received adjuvant systemic therapy. The SNB-only group had more micrometastases than the ALND group (44.8% vs. 37.5%, P=0.05), and 27% of the ALND patients had additional lymph node metastases beyond the SLN. At a median follow-up of 6.3 years, there was no statistically significant difference between the two groups in terms of locoregional recurrence (1.6% with SNB and 3.1% with ALND), DFS (83.9% with SNB and 82.2% with ALND), and OS (92.5% with SNB and 91.8% with ALND). The AMAROS trial was also a prospective, multicenter Phase III non-inferiority trial that enrolled 4,823 patients between 2001 and 2010 (9). Of the 1,425 patients with a positive SLN, 744 had been assigned to receive ALND, and 681 to axillary radiotherapy. The SLN was considered to have metastasis if any tumor deposit was found, including that identified on IHC which was employed when H&E was negative. Eighty-two percent of the patients in each arm had BCS with WBI while the remaining 18% had mastectomy with or without chest wall radiation. Thirty-three percent of the ALND group had additional lymph node metastases removed by ALND. At a median follow up of 6.1 years, there was no statistically significant difference in axillary recurrence (0.4% with ALND and 1.2% with axillary radiotherapy), DFS (86.9% vs. 82.7%), and OS (93.3% vs. 92.5%). Significantly higher rates of morbidities with ALND compared to either SNB-alone or axillary radiotherapy were demonstrated. These studies provided level one evidence that completion ALND may be omitted in select patients with early stage breast cancer with limited SLN metastasis who are treated with BCS with WBI and adjuvant systemic therapy without compromising locoregional control or survival. The AMAROS trial further demonstrated that perhaps in select mastectomy patients, completion ALND may be omitted as well.


SLN micrometastases

SNB not only revolutionized the approach to axillary staging in early stage invasive breast cancer, but it also led to more intensive evaluation of the SLN and higher rates of detection of micrometastases and ITCs. These tumor cells are usually not detected on initial H&E stains but on further pathologic evaluation with deeper-cut H&E analysis, IHC stains, or molecular testing. Multiple sectioning of the SLN and evaluation with IHC have been shown to improve the accuracy of axillary staging, especially in the detection of micrometastases, compared to routine histologic examination of non-SLN in ALND with one or two sections (23).

Molecular analysis of SLNs with reverse transcription-polymerase chain reaction (RT-PCR) has been shown to be more sensitive and more accurate for lymph node metastases compared to standard histologic evaluation. In a prospective multisite study, quantitative RT-PCR detected 98% of metastases >2 mm and 88% of metastases greater than >0.2 mm, a superior result to frozen section histology (24). The molecular assay could also be performed in 36–46 minutes for one to three nodes (25). Despite its higher sensitivity than standard histology, molecular analysis of SLNs has not been shown to provide additional prognostic information. In a prospective multicenter study of 547 patients with a mean follow-up of 7 years, molecular staging predicted only 26% of recurrences in patients with negative SLNs by conventional histology, and it was not a statistically significant independent predictor of distant recurrence (26). Similar results were observed in another prospective study of 501 patients with a follow-up of 5 years, which failed to demonstrate a significant clinical impact with molecular overexpression of breast cancer-associated genes in lymph nodes (27).

The prognostic significance of micrometastases has been largely debated. Some older retrospective data associated occult metastases with worse survival, but those patients were not treated with current standards of adjuvant systemic therapy. The Ludwig Breast Cancer Study Group identified occult nodal metastases in 20% of the study patients (28). Less than half of them received adjuvant systemic therapy in the form of cyclophosphamide, methotrexate and fluorouracil as part of the randomization process. A SEER database review demonstrated nodal micrometastasis as a prognostic survival indictor, intermediate to N0 and N1 disease (29). A retrospective Dutch study showed nodal ITCs and micrometastases to be associated with decreased survival, but only in patients who did not receive adjuvant systemic therapy (30).

The ACOSOG Z0010 trial was a prospective clinical trial undertaken to resolve the conflicting data on micrometastases (31). This was a prospective observational study of patients with clinical T1,2N0M0 invasive breast cancer treated with breast conservation, SNB, and bilateral iliac crest bone marrow aspirations. Between 1999 and 2003, 5,538 patients were enrolled in the study, and 5,519 patients were eligible and had a SLN identified, of whom 23.7% had SLN metastases detected by H&E. Of the remaining H&E-negative SLNs that were evaluated centrally and blindly by IHC, 349 (10.5%) had tumor detected immunohistochemically. At a median follow up of 6.3 years, SLN metastases detected by IHC alone did not have a significant impact on DFS or OS. A subset analysis of the NSABP-B32 trial evaluated the prognostic significance of occult metastases (32). Of 3,887 tissue blocks of pathologically negative SLN specimen that were re-examined with serial sectioning and with IHC, 15.9% were detected with occult metastases. The estimated 5-year overall survival was 94.6% with occult metastases and 95.8% without (P=0.03). Despite the statistically significant difference, the authors concluded, based on the very small absolute difference in OS, that further evaluation of H&E-negative SLNs would not provide additional clinical benefit. This conclusion was reinforced by the IBCSG 23-01 trial that randomized patients with SLN micrometastases, 464 to the ALND arm and 467 to no-ALND, from 2001 to 2010 (33). The SLNs were evaluated on frozen or permanent sections with H&E on multiple sections and with IHC only in cases of suspicious or negative H&E findings. ITCs were included but not macrometastatic disease. At a median follow-up of 5 years, there was no statistically significant difference in DFS (87.8% with no ALND vs. 84.4% with ALND) and OS (97.5% vs. 97.6%) with a similar 5-year cumulative incidence of breast cancer events.

The most recent 7th edition of the AJCC TNM staging system on breast cancer incorporated changes reflecting the prognostic significance of micrometastases (11). Stage I has been subdivided into stage 1A and stage 1B to differentiate T1 tumors with micrometastases (N1mic, Stage 1B) from those with negative nodes (Stage 1A). The stage 1B designation has been challenged by Mittendorf et al. who analyzed over 8,000 patients from two prospective cohorts, an MD Anderson Cancer Center series and the ACOSOG Z0010 cohort (34). Five thousand stage 1A patients and 580 stage 1B patients were identified with a median follow-up of 6.1 to 9 years. There was no statistically significant difference between the two stages with respect to recurrence-free survival, DFS and OS. One of the limitations of the study was the increased use of adjuvant systemic therapy in stage 1B patients compared to stage 1A. Despite this, the study calls into question the current staging nomenclature that reflects only the anatomical classification whereas treatment of breast cancer is increasingly driven by tumor biology with growing use of genomic assays irrespective of tumor stage.


SNB after neoadjuvant chemotherapy (NAC)

Controversy exists regarding SNB after NAC as it is unclear how NAC affects lymphatic drainage patterns or if it leads to non-uniform eradication of disease which would result in reduced accuracy and high FNRs. In the NSABP-B27 study which compared three arms of NAC, 428 patients had SNB attempted before the required ALND with a SLN identification rate of 85% (35). Of 343 patients who had both SNB and ALND, the FNR was 10.7%, similar to that reported in NSABP-B32. More than 75% of the patients who had SNB were clinically node-negative prior to NAC. One limitation of the study is the lack of a predetermined protocol for the SNB procedure and of standardized pathologic assessment of SLNs. In a meta-analysis of 21 studies with 1,273 patients who had SNB followed by ALND after NAC, the SLN identification rate was 90% with a FNR of 12% (36). A small retrospective study of 69 patients who had cytologically proven axillary lymph node disease prior to NAC reported a FNR of 25%, much higher than that observed in clinically node-negative patients (37).

The ACOSOG Z1071 trial was designed to evaluate the role of SNB following NAC for initially clinically node-positive disease (38). Between 2009 to 2011, 756 patients with clinical T0−4, N1−2, M0 breast cancer were enrolled. Of the 649 patients with cN1 disease who underwent NAC followed by SNB and ALND, the SLN identification rate was 92.9%. With the removal of 2 or more SLNs, the FNR was 12.6% which was higher than the preset acceptable threshold of 10%. In the SENTINA trial, a four-arm prospective cohort study designed to assess the optimal algorithm for SNB in relation to NAC, one of the arms consisted of 592 patients with clinically node-positive disease who converted to clinically node-negative status following NAC (39). These patients underwent SNB followed by ALND after NAC with a SLN identification rate of 80.1% and a FNR of 14.2%. Both studies concluded that SNB may not be a reliable alternative to ALND following NAC for initially clinically node-positive breast cancer.


Recommendations

In light of results from ACOSOG Z0010, Z0011, and NSABP-B32, the American Society of Breast Surgeons (ASBS) released a position statement on management of the axilla in August 2011 (https://www.breastsurgeons.org/statements/PDF_Statements/Axillary_Management.pdf). It states that ALND may no longer be routinely required for patients with T1-2 tumors, 1 to 2 positive SLNs without extracapsular extension, who are treated with BCS, WBI and adjuvant systemic therapy. It recommended against routine use of IHC on SLNs. In addition, intraoperative frozen section analysis of the SLN can be avoided if clinical suspicion of nodal involvement is low and the patient otherwise would meet the entry criteria for the Z0011 trial.

In 2014, the American Society of Clinical Oncology (ASCO) updated its evidence-based guidelines on SNB for early stage breast cancer based on nine randomized clinical trials and 13 cohort studies between 2004 and 2013 (1). It recommended against ALND for patients with one or two metastatic SLNs who are undergoing BCS followed by WBI. Patients with metastatic SLNs undergoing mastectomy should be offered ALND. It also stated that SNB may be offered in selected patients with multicentric tumors, DCIS with planned mastectomy, prior axillary surgery, and NAC. SNB is not recommended for large or locally advanced invasive breast cancers, inflammatory breast cancer, DCIS with planned breast conservation surgery, or in pregnancy. The updates recommended against the routine use of multiple sectioning or IHC for detection of occult metastases that may be present in SLNs that are tumor-free on initial pathology evaluation of a single routinely stained section. They acknowledged the lack of standardized methods to evaluate SLNs in different studies and the varied practice patterns across regions in the world. Thus the authors, based on the expert opinion of the Update Committee, recommended quantification of nodal tumor burden by the pathologist as part of the standard analysis.


Conclusions

The advent of SNB represents one of the greatest achievements in breast cancer management in the past decades. It has replaced ALND for axillary staging in clinically node-negative patients and even in some who have positive SLNs. Even though axillary nodal status remains one of the most important prognostic factors in breast cancer, the importance of biology in prognosis and guiding therapy is being increasingly recognized. In addition, the importance of radiotherapy and systemic therapy in optimizing breast cancer management cannot be understated. Clinicians and pathologists should be aware of the significance of metastases in SLNs, even single tumor cells, and formulate therapeutic plans based on not only the exact extent of nodal disease but also the molecular subtype of the tumor and genomic analyses.


Acknowledgements

This work was supported by the Margie and Robert E. Petersen Foundation, the Fashion Footwear Charitable Foundation of New York, Inc., and the Associates for Breast and Prostate Cancer Studies.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014;32:1365-83. [Crossref] [PubMed]
  2. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-8; discussion 398-401. [Crossref] [PubMed]
  3. Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50. [PubMed]
  4. Turner RR, Ollila DW, Krasne DL, et al. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-6; discussion 276-8. [Crossref] [PubMed]
  5. Weaver DL, Krag DN, Ashikaga T, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000;88:1099-107. [Crossref] [PubMed]
  6. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881-8. [Crossref] [PubMed]
  7. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999;91:368-73. [Crossref] [PubMed]
  8. Gill G; SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009;16:266-75. [Crossref] [PubMed]
  9. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:1303-10. [Crossref] [PubMed]
  10. Fitzgibbons PL. LiVolsi VA. Recommendations for handling radioactive specimens obtained by sentinel lymphadenectomy. Surgical Pathology Committee of the College of American Pathologists, and the Association of Directors of Anatomic and Surgical Pathology. Am J Surg Pathol 2000;24:1549-51. [Crossref] [PubMed]
  11. Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
  12. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-33. [Crossref] [PubMed]
  13. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010;251:595-600. [Crossref] [PubMed]
  14. Canavese G, Catturich A, Vecchio C, et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 2009;20:1001-7. [Crossref] [PubMed]
  15. Zavagno G, De Salvo GL, Scalco G, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008;247:207-13. [Crossref] [PubMed]
  16. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946-53. [Crossref] [PubMed]
  17. Yi M, Giordano SH, Meric-Bernstam F, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol 2010;17 Suppl 3:343-51. [Crossref] [PubMed]
  18. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003;10:1140-51. [Crossref] [PubMed]
  19. Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg 2005;190:543-50. [Crossref] [PubMed]
  20. Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 2012;255:109-15. [Crossref] [PubMed]
  21. Park J, Fey JV, Naik AM, et al. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007;245:462-8. [Crossref] [PubMed]
  22. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569-75. [Crossref] [PubMed]
  23. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995;222:394-9; discussion 399-401. [Crossref] [PubMed]
  24. Blumencranz P, Whitworth PW, Deck K, et al. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 2007;194:426-32. [Crossref] [PubMed]
  25. Julian TB, Blumencranz P, Deck K, et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol 2008;26:3338-45. [Crossref] [PubMed]
  26. Verbanac KM, Min CJ, Mannie AE, et al. Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases. Ann Surg Oncol 2010;17 Suppl 3:368-77. [Crossref] [PubMed]
  27. Fisher CS, Cole DJ, Mitas M, et al. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes fails to predict breast cancer recurrence: a final analysis of a prospective multi-institutional cohort study. Ann Surg Oncol 2010;17 Suppl 3:312-20. [Crossref] [PubMed]
  28. Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900. [Crossref] [PubMed]
  29. Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 2007;14:3378-84. [Crossref] [PubMed]
  30. de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009;361:653-63. [Crossref] [PubMed]
  31. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011;306:385-93. [Crossref] [PubMed]
  32. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011;364:412-21. [Crossref] [PubMed]
  33. Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297-305. [Crossref] [PubMed]
  34. Mittendorf EA, Ballman KV, McCall LM, et al. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol 2015;33:1119-27. [Crossref] [PubMed]
  35. Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-702. [Crossref] [PubMed]
  36. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 2006;93:539-46. [Crossref] [PubMed]
  37. Shen J, Gilcrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 2007;109:1255-63. [Crossref] [PubMed]
  38. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:1455-61. [Crossref] [PubMed]
  39. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;14:609-18. [Crossref] [PubMed]
Cite this article as: Bao J, Donovan C, Chung A, Giuliano AE. The staging value of sentinel lymph node biopsy for breast cancer: translating pathologic findings to clinical practice. Chin Clin Oncol 2016;5(3):36. doi: 10.21037/cco.2016.03.17

Refbacks

  • There are currently no refbacks.